trial

Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism

NCTId NCT00287820
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 46 (estimated)
Sponsored by Nathan Kline Institute for Psychiatric Research
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
46 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2004-02
Primary completion
—
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
OlanzapineRisperidone

Sponsors

Nathan Kline Institute for Psychiatric ResearchLead Sponsor
Eli Lilly and CompanyCollaborator

Investigators

1
Robert C. Smith, MD, PhDPrincipal Investigator

Sites

1 total
New York, United States

Facts & assertions

3 sourced
Enrollment
46
Phase
PHASE4
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
Risperidone
drug
lead_sponsor
Nathan Kline Institute for Psychiatric Research
company
collaborator
Eli Lilly and Company
company
indication
Diabetes
indication
Hyperglycemia
indication
Insulin Resistance
indication
investigator
Robert C. Smith, MD, PhD
person